Pradaxa (Atrial Fibrillation) - Analysis and Forecasts to 2022

NEW YORK, June 14, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pradaxa (Atrial Fibrillation) - Analysis and Forecasts to 2022

http://www.reportlinker.com/p0886895/Pradaxa-Atrial-Fibrillation---Analysis-and-Forecasts-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory

Pradaxa (Atrial Fibrillation) - Analysis and Forecasts to 2022

Summary

GlobalData's pharmaceuticals report, "Pradaxa (Atrial Fibrillation) - Analysis and Forecasts to 2022" provides Pradaxa global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2011-2022). The report also includes information on Atrial Fibrillation market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)

- Analysis and review of Pradaxa including sales data

- Qualitative and quantitative assessment of market space

- Analysis of the trends, drivers and restraints shaping and defining the markets

- In-depth analysis of Pradaxa including efficacy, safety, pricing, competition and other details which influence its sales potential

- Global sales forecast for 2011-2022 for Pradaxa

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of competition by understanding the changing competitive landscape

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of the drug's performance

- Examine the historical sales performance of a drug in seven major markets

- Obtain sales forecast for currently marketed/pipeline drug for 2011-2022 for all seven major markets

1 Table of contents

1 Table of contents 2

1.1 List of Tables 3

1.2 List of Figures 3

2 Introduction 4

2.1 Atrial Fibrillation Market 4

2.2 Epidemiology 4

2.3 Etiology and Risk Factors 5

2.3.1 Symptoms associated with AF 6

2.4 GlobalData Analysis and Forecasts Report Guidance 7

3 Atrial Fibrillation: Market Characterization 8

3.1 Atrial Fibrillation Market 8

3.2 Atrial Fibrillation Market Forecasts and CAGR 9

3.3 Drivers of Atrial Fibrillation Market 9

3.3.1 High Unmet need 9

3.3.2 Strong Pipeline 10

3.3.3 Increase in prevalence and ageing populations 10

3.3.4 Organisation of Awareness Campaigns 11

3.4 Barriers in Atrial Fibrillation Market 12

3.4.1 Limitations in established therapies 12

3.4.2 High cost of emerging therapies 12

4 Classification in Atrial Fibrillation: Introduction 13

4.1 AF Classification 13

4.1.1 Pathophysiology of AF 14

4.1.2 Diagnosis in Atrial Fibrillation 15

4.1.3 Impact of Atrial Fibrillation 16

5 Treatment Options and Management in Atrial Fibrillation 17

5.1 Rate control and Rhythm control 17

5.2 Rate Control Versus Rhythm Control 19

6 Pradaxa 20

6.1 Introduction 20

6.2 Mechanism of Action 20

6.3 Clinical Studies 20

6.4 Approval History of Pradaxa 22

6.5 Factors Affecting Sales of Pradaxa 22

6.5.1 New option to standard blood thinners 22

6.5.2 First oral anticoagulant for 50 years 22

6.5.3 Convenient dosing with no monitoring 22

6.5.4 NICE recommendation of Pradaxa's usage for stroke prevention in AF in the UK 22

6.6 Drug Evaluation 23

6.6.1 Drug Risk Benefit Score 23

6.6.2 Relative Efficacy 23

6.6.3 Safety 23

6.6.4 Compliance 23

6.6.5 Dosing Convenience 23

6.6.6 Intensity of Competition 23

6.7 Sales Forecast 24

6.7.1 Target Patient Pool of Pradaxa 24

6.7.2 Dosing 25

6.7.3 Market Penetration 25

6.7.4 Annual Cost of Therapy 25

6.7.5 Sales Projections of Pradaxa 26

7 Appendix 35

7.1 Market Definitions 35

7.2 Abbreviations 35

7.3 Research Methodology 35

7.3.1 Coverage 35

7.3.2 Secondary Research 36

7.3.3 Forecasting 36

7.3.4 Number of Patients Approved to Take the Drug 36

7.3.5 Net Penetration of Drug 37

7.3.6 Net Annual Dosing 37

7.3.7 Annual Cost of Therapy 37

7.4 Drug Sales Estimates Model 37

7.5 Contact Us 37

7.6 Disclaimer 38

7.7 Sources 38

List of Tables

Table 1: Epidemiology of Atrial Fibrillation (2011) 5

Table 2: Increase in the Risk of AF in The Presence of Risk Factors 5

Table 3: Stratification of All Risk Factors For Atrial Fibrillation 5

Table 4: Atrial Fibrillation Classification 14

Table 5: Treatment Guidelines For The Management of Atrial Fibrillation 17

Table 6: Clinical Trial Results First Occurrence Of Stroke Or Systemic Embolism In The RE-LY Study 21

Table 7: Clinical Trial Results For Strokes And Systemic Embolism In The RE-LY Study 21

Table 8: Clinical Trial Results Of Center INR Control In The RE-LY Study 21

Table 9: Approval History Of Pradaxa 22

Table 10: Drug Risk Benefit Score Of Pradaxa 23

Table 11: Pradaxa, Atrial Fibrillation, Global, Annual Cost Of Therapy, 2011 25

Table 12: Pradaxa, Atrial Fibrillation, Global Sales Forecasts ($m), 2010-2022 26

Table 13: Pradaxa, Atrial Fibrillation, The US, Sales Forecast ($m), 2010-2022 27

Table 14: Pradaxa, Atrial Fibrillation, The UK, Sales Forecasts ($m), 2011-2022 28

Table 15: Pradaxa, Atrial Fibrillation, France, Sales Forecasts ($m), 2011-2022 29

Table 16: Pradaxa, Atrial Fibrillation, Germany, Sales Forecasts ($m), 2011-2022 30

Table 17: Pradaxa, Atrial Fibrillation, Italy, Sales Forecasts ($m), 2011-2022 31

Table 18: Pradaxa, Atrial Fibrillation, Spain, Sales Forecasts ($m), 2011-2022 32

Table 19: Pradaxa, Atrial Fibrillation, Japan, Sales Forecasts ($m), 2011-2022 33

List of Figures

Figure 1: Atrial Fibrillation, Global Market Size Forecasts ($bn), 2011–2022 9

Figure 2: Percentage Of Molecules (in Different Phases of Development) For Atrial Fibrillation 10

Figure 3: Increase of Prevalance Population In Atrial Fibrillation 11

Figure 4: Normal Heart Rhythm Vs Atrial Fibrillation 13

Figure 5: Broad Classification Of Patterns In Atrial Fibrillation 14

Figure 6: Disease States Associated With Atrial Fibrillation, By (%) 15

Figure 7: Therapeutic Goals In Patients With Atrial Fibrillation (AF) 18

Figure 8: Management of Newly Discovered Atrial Fibrillation (AF) 18

Figure 9: Drug Model Diagram Of Pradaxa 24

Figure 10: Pradaxa, Atrial Fibrillation, Global Sales Forecast s($m), 2010-2022 26

Figure 11: Pradaxa, Atrial Fibrillation, The US, Sales Forecast ($m), 2010-2022 27

Figure 12: Pradaxa, Atrial Fibrillation, The UK, Sales Forecast ($m), 2011-2022 28

Figure 13: Pradaxa, Atrial Fibrillation, France, Sales Forecast ($m), 2011-2022 29

Figure 14: Pradaxa, Atrial Fibrillation, Germany, Sales Forecast ($m), 2011-2022 30

Figure 15: Pradaxa, Atrial Fibrillation, Italy, Sales Forecast ($m), 2011-2022 31

Figure 16: Pradaxa, Atrial Fibrillation, Spain, Sales Forecast ($m), 2011-2022 32

Figure 17: Pradaxa, Atrial Fibrillation, Japan, Sales Forecast ($m), 2011-2022 33

Figure 18: Pradaxa, Atrial Fibrillation, Global Sales Distribution (By %) (By Country), 2017 34

Figure 19: Patients Approved For The Drug 36

To order this report:

: Pradaxa (Atrial Fibrillation) - Analysis and Forecasts to 2022

Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker